[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587897":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":45,"centralContacts":49,"locations":58,"responsibleParty":199,"collaborators":201,"id":205,"slug":206,"hasResults":207,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":31,"eligibilityCriteria":211,"healthyVolunteers":207,"sex":212,"minAge":213,"maxAge":31,"enrollmentInfo":214,"targetDuration":31,"studyType":217,"phases":218,"briefSummary":220,"conditions":221,"keywords":31,"overallStatus":61,"whyStopped":31,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":232},{"fullName":5,"class":6},"Yale University","OTHER",[8,16,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Intracranial Thalamic and Cortical Recording (Aim 3A)","EXPERIMENTAL","Participants will perform the visual behavioral task with intracranial electroencephalogram (EEG) brain recordings carried out in parallel with surface EEG recordings. For Aim 3A, we will analyze thalamic event related potentials in perceived vs not perceived stimuli, classified as in perception of no report visual stimuli based on eye metrics.",[13,14,15],"Device: EEG","Device: Eye Tracking","Device: Behavioral task",{"label":17,"type":10,"description":18,"interventionNames":19},"Thalamic Stimulation (Aim 3B)","We will test participants during the Visual Report Paradigm, while recording from the intralaminar thalamus with simultaneous scalp EEG as in Aim 3A. Three thalamic stimulation conditions will be tested, randomized across trials: 1. No stimulation; 2. Stimulation Concurrent with visual stimuli; 3. Stimulation Delayed to 2s after visual stimuli. Stimulation will be a 100Hz train lasting 300ms, with biphasic square wave pulses 120μs per phase, current adjusted previously by clinicians to maximum tolerated level without side effects (typically \\~3mA).\n\nThe electrical stimulation is being delivered for research purposes to understand the causal role of thalamus in regulating visual perception.",[13,14,15],{"label":21,"type":10,"description":22,"interventionNames":23},"fMRI with report + no-report perception paradigms (Aims 1 and 2)","Participants will consist of healthy adults undergoing fMRI, eye metric and behavioral testing with report + no-report perception paradigms. This will include prospective data collection for the auditory paradigm, tactile paradigm, as well as analysis of an existing data set for the visual paradigm.",[13,14,15,24],"Diagnostic Test: fMRI",[26,32,36,40],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DEVICE","EEG","Participants will have scalp EEG recorded with the international 10-20 system sampled at 256Hz using EEG amplifiers for purposes of surface event related potential analysis",[9,17,21],null,{"type":27,"name":33,"description":34,"armGroupLabels":35,"otherNames":31},"Eye Tracking","An eye-tracking device may be used during the perceptual awareness task. Pupillary and gaze location measurements are recorded using either a ViewPoint\\~VoltagePro.EyeLink 1000 Plus system, or Argus Science ETVision system. If using the ViewPoint\\~VoltagePro system or the Argus Science ETVision system, participants will be asked to wear an eye tracker during the perceptual awareness task (similar to wearing sunglasses). If using the EyeLink 1000 Plus system, participants may be asked to place their head inside of a padded head-chin rest to stabilize head position",[9,17,21],{"type":27,"name":37,"description":38,"armGroupLabels":39,"otherNames":31},"Behavioral task","For the visual perceptual awareness task, the participant will be presented with barely perceptible visual stimuli. After a variable delay, the participant will be asked to report perception of each stimulus and identify its location.",[9,17,21],{"type":41,"name":42,"description":43,"armGroupLabels":44,"otherNames":31},"DIAGNOSTIC_TEST","fMRI","Visual, auditory or tactile behavioral task will be performed during fMRI at the Yale MR Center. The subject will be asked to lie still in a 3T magnet scanner for up to 15-minute blocks. Each subject will have a sagittal T1-weighted localizer scan (3 minutes) and axial-oblique T1-weighted images (3 min). Multiple 5-15-minute imaging runs will be repeated up to 10 times. The subjects' responses will be recorded by a computer that is linked to the button box. The stimuli will be presented in blocks of 5 to 15 minutes throughout the MR imaging sequences.",[21],[46],{"name":47,"affiliation":5,"role":48},"Hal Blumenfeld, MD, Phd","PRINCIPAL_INVESTIGATOR",[50,55],{"name":51,"role":52,"phone":53,"phoneExt":31,"email":54},"Hal Blumenfeld, MD, PHD","CONTACT","(203) 785-3865","Hal.blumenfeld@yale.edu",{"name":56,"role":52,"phone":31,"phoneExt":31,"email":57},"Kristine Dacosta","kristine.dacosta@yale.edu",[59,82,98,116,132,149,165,181],{"facility":60,"status":61,"city":62,"state":63,"zip":64,"country":65,"countryCode":66,"cosmosGeoPoint":67,"geoPoint":72,"contacts":73},"Yale School of Medicine","RECRUITING","New Haven","Connecticut","06520","United States","US",{"type":68,"coordinates":69},"Point",[70,71],-72.92816,41.30815,{"lat":71,"lon":70},[74,77,79],{"name":75,"role":52,"phone":31,"phoneExt":31,"email":76},"Francois Stockart","francois.stockart@yale.edu",{"name":78,"role":48,"phone":31,"phoneExt":31,"email":31},"Hal Blumenfeld, MD, PhD",{"name":80,"role":81,"phone":31,"phoneExt":31,"email":31},"Imran Quraishi, MD, PhD","SUB_INVESTIGATOR",{"facility":83,"status":61,"city":84,"state":85,"zip":86,"country":65,"countryCode":66,"cosmosGeoPoint":87,"geoPoint":91,"contacts":92},"University of Kansas Medical Center","Kansas City","Kansas","66160",{"type":68,"coordinates":88},[89,90],-94.62746,39.11417,{"lat":90,"lon":89},[93,96],{"name":94,"role":52,"phone":31,"phoneExt":31,"email":95},"Laura Crabtree","lcrabtree2@kumc.edu",{"name":97,"role":48,"phone":31,"phoneExt":31,"email":31},"Utku Uysal, MD, MS",{"facility":99,"status":61,"city":100,"state":101,"zip":102,"country":65,"countryCode":66,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"Massachusetts General Hospital","Boston","Massachusetts","02114",{"type":68,"coordinates":104},[105,106],-71.05977,42.35843,{"lat":106,"lon":105},[109,112,114],{"name":110,"role":52,"phone":31,"phoneExt":31,"email":111},"Erin Kaye Donahue, PhD","ekdonahue@mgh.harvard.edu",{"name":113,"role":48,"phone":31,"phoneExt":31,"email":31},"Mark Richardson, MD, PhD",{"name":115,"role":81,"phone":31,"phoneExt":31,"email":31},"Peter Hadar, MD",{"facility":117,"status":61,"city":118,"state":119,"zip":120,"country":65,"countryCode":66,"cosmosGeoPoint":121,"geoPoint":125,"contacts":126},"Mayo Clinic","Rochester","Minnesota","55901",{"type":68,"coordinates":122},[123,124],-92.4699,44.02163,{"lat":124,"lon":123},[127,130],{"name":128,"role":52,"phone":31,"phoneExt":31,"email":129},"Ana Sanchez","sanchez.ana2@mayo.edu",{"name":131,"role":48,"phone":31,"phoneExt":31,"email":31},"Jamie Van Gompel, MD",{"facility":133,"status":134,"city":135,"state":136,"zip":137,"country":65,"countryCode":66,"cosmosGeoPoint":138,"geoPoint":142,"contacts":143},"Dartmouth Hitchcock Medical Center","NOT_YET_RECRUITING","Lebanon","New Hampshire","03756",{"type":68,"coordinates":139},[140,141],-72.25176,43.64229,{"lat":141,"lon":140},[144,147],{"name":145,"role":52,"phone":31,"phoneExt":31,"email":146},"Anastasia Kanishcheva, MPH","anastasia.kanishcheva@hitchcock.org",{"name":148,"role":48,"phone":31,"phoneExt":31,"email":31},"Barbara Jobst, MD",{"facility":150,"status":134,"city":151,"state":152,"zip":153,"country":65,"countryCode":66,"cosmosGeoPoint":154,"geoPoint":158,"contacts":159},"University of Pittsburgh Medical Center","Pittsburgh","Pennsylvania","15260",{"type":68,"coordinates":155},[156,157],-79.99589,40.44062,{"lat":157,"lon":156},[160,163],{"name":161,"role":52,"phone":31,"phoneExt":31,"email":162},"Dane Prince","dep137@pitt.edu",{"name":164,"role":48,"phone":31,"phoneExt":31,"email":31},"Alexandra Urban, MD",{"facility":166,"status":61,"city":167,"state":168,"zip":169,"country":65,"countryCode":66,"cosmosGeoPoint":170,"geoPoint":174,"contacts":175},"Vanderbilt University Medical Center","Nashville","Tennessee","37235",{"type":68,"coordinates":171},[172,173],-86.78444,36.16589,{"lat":173,"lon":172},[176,179],{"name":177,"role":52,"phone":31,"phoneExt":31,"email":178},"Kate Wang","kate.wang.1@vumc.org",{"name":180,"role":48,"phone":31,"phoneExt":31,"email":31},"Dario Englot, MD, PhD",{"facility":182,"status":61,"city":183,"state":184,"zip":185,"country":65,"countryCode":66,"cosmosGeoPoint":186,"geoPoint":190,"contacts":191},"Baylor College of Medicine","Houston","Texas","77030",{"type":68,"coordinates":187},[188,189],-95.36327,29.76328,{"lat":189,"lon":188},[192,195,197],{"name":193,"role":52,"phone":31,"phoneExt":31,"email":194},"Victoria Gates","victoria.gates@bcm.edu",{"name":196,"role":48,"phone":31,"phoneExt":31,"email":31},"Sameer Anil Sheth, MD, PhD",{"name":198,"role":81,"phone":31,"phoneExt":31,"email":31},"Vaishnav Krishnan, MD, PhD",{"type":200,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR",[202],{"name":203,"class":204},"National Institute of Neurological Disorders and Stroke (NINDS)","NIH","100587897","subcortical-arousal-in-perceptual-awareness-100587897",false,"NCT06934356","Subcortical Arousal in Perceptual Awareness","Shared Subcortical Arousal Systems Across Perceptual Modalities","A. The following are the inclusion\u002Fexclusion criteria for healthy participants age 18 years and up (Aim 1 and 2):\n\nInclusion: (1) normal vision with or without the use of corrective lenses; (2) normal hearing not needing an assistive hearing device.\n\nExclusion: (1) past history of diagnosis of a psychiatric or neurologic disease; (2) current psychiatric or neurologic disease; (3) requires hard contact lenses or glasses to maintain normal vision (prevents accurate pupil and eye gaze measurements); (4) pregnant or nonremovable ferrous metal objects inside or on the body (prevents MRI).\n\nB. The following are the inclusion\u002Fexclusion criteria for epilepsy patients with thalamic electrodes age 13 years and up (Aim 3A):\n\nInclusion: (1) normal vision with or without the use of corrective lenses\n\nExclusion: (1) severe vision impairment even with correction preventing ability to see stimuli (prevents accurate pupil and eye gaze measurements); (2) unable to perform the perception task due to cognitive impairment. All participants must be capable of consenting for themselves.\n\nC. The following are the inclusion\u002Fexclusion criteria for epilepsy patients with thalamic electrodes age 18 year and up (Aim 3B):\n\nInclusion: (1) normal vision with or without the use of corrective lenses; (2) A female subject must have a negative pregnancy test and if sexually active, must be using a reliable form of birth control for the duration of the trial, be surgically sterile, or be at least two years post-menopausal.\n\nExclusion: (1) severe vision impairment even with correction preventing ability to see stimuli (prevents accurate pupil and eye gaze measurements); (2) unable to perform the perception task due to cognitive impairment. All participants must be capable of consenting for themselves; (3) Pregnancy.","ALL","13 Years",{"count":215,"type":216},202,"ESTIMATED","INTERVENTIONAL",[219],"NA","The study consists of prospective enrollment of healthy participants and patients with epilepsy, as well as analysis of an existing data set. Healthy participants will be studied with fMRI, eye metrics and behavioral testing at Yale. Patients will be studied with intracranial thalamic and cortical recording and stimulation, eye metrics and behavioral testing.",[222],"Epilepsy","2026-06-08",{"date":225,"type":226},"2026-06-10","ACTUAL",{"date":228,"type":226},"2025-10-13",{"date":230,"type":216},"2030-12",{"name":5,"class":6},8]